Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Mar;18(1):17-25.
doi: 10.1023/a:1021974517837.

Effect of leucine administration on creatine kinase activity in rat brain

Affiliations

Effect of leucine administration on creatine kinase activity in rat brain

Carmen Pilla et al. Metab Brain Dis. 2003 Mar.

Abstract

Maple syrup urine disease (MSUD) is a metabolic disorder biochemically characterized by the accumulation of branched-chain amino acids (BCAA) and their branched-chain keto acids (BCKA) in blood and tissues. Neurological dysfunction is usually present in the patients, but the pathophysiology of brain damage is still obscure. Considering that brain energy metabolism is possibly altered in MSUD, the main objective of this study was to determine creatine kinase activity in the brain of rats subjected to acute and chronic administration of leucine. Chronic hyperleucinemia was induced by subcutaneous administrations of 4.8 micromol leucine/g body weight, twice a day, from the 6th to the 21st postnatal day. For acute hyperleucinemia, 21-day-old rats received three administrations of the amino acid at 3 h interval. Twelve hours after the chronic treatment or 1 h after the acute one, rats were killed and creatine kinase activity measured. The results indicated that acute or chronic administration of leucine altered creatine kinase activity in the brain of leucine-treated rats. Considering the crucial role creatine kinase plays in energy homeostasis in brain, if these effects also occur in the brain of MSUD patients, it is possible that alteration of this enzyme activity may contribute to the brain damage found in this disease.

PubMed Disclaimer

References

    1. Acta Paediatr. 1964 Jul;53:356-64 - PubMed
    1. Clin Chim Acta. 1962 Sep;7:597-603 - PubMed
    1. Neurochem Res. 1997 Sep;22(9):1159-64 - PubMed
    1. J Neurochem. 2001 Jan;76(2):425-34 - PubMed
    1. J Neurochem. 1991 Jun;56(6):2101-7 - PubMed

Publication types

LinkOut - more resources